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Abstract
Background: Verrucae are a common, infectious and sometimes painful problem. The optimal treatment for
verrucae is unclear due to a lack of high quality randomised controlled trials. The primary objective of this study is
to compare the clinical effectiveness of two common treatments for verrucae: cryotherapy using liquid nitrogen
versus salicylic acid. Secondary objectives include a comparison of the cost-effectiveness of the treatments, and an
investigation of time to clearance of verrucae, recurrence/clearance of verrucae at six months, patient satisfaction
with treatment, pain associated with treatment, and use of painkillers for the treatments.
Methods/Design: This is an open, pragmatic, multicentre, randomised controlled trial with two parallel groups:
cryotherapy using liquid nitrogen delivered by a healthcare professional for a maximum of 4 treatments
(treatments 2-3 weeks apart) or daily self-treatment with 50% salicylic acid for a maximum of 8 weeks. Two
hundred and sixty-six patients aged 12 years and over with a verruca are being enrolled into the study. The
primary outcome is complete clearance of all verrucae as observed on digital photographs taken at 12 weeks
compared with baseline and assessed by an independent healthcare professional. Secondary outcomes include
self-reported time to clearance of verrucae, self-reported clearance of verrucae at 6 months, cost-effectiveness of
the treatments compared to one another, and patient acceptability of both treatments including possible side
effects such as pain. The primary analysis will be intention to treat. It is planned that recruitment will be completed
by December 2009 and results will be available by June 2010.
Trial registration: Current Controlled Trials ISRCTN18994246.
Background
Verrucae or plantar warts are a common, infectious and
sometimes painful problem. Although most verrucae
will spontaneously disappear without treatment many
patients seek treatment to remove a verruca due to it
being painful or because they are being prevented from
doing sports and other activities of daily living. Two
common treatments for verrucae are cryotherapy using
liquid nitrogen which involves freezing the tissues at
below -60C or application of a salicylic acid paste which
macerates the skin. Using incidence figures from the 4th
National Morbidity Survey [1], an economic decision
model assessing the effectiveness and cost-effectiveness
of salicylic acid and cryotherapy has estimated that
almost 2 million people in England and Wales see their
General Practitioner (GP) per year about cutaneous
warts at a cost of at least £40 million per annum [2].
A systematic review conducted by the Cochrane Skin
Group assessed the effects of different local treatments
of cutaneous, non-genital warts in healthy people [3].
This review highlighted the uncertainty with respect to
the optimal treatment of verrucae. There was, however,
some evidence from six trials to suggest that treatment
with salicylic acid was more effective than placebo/no
treatment, odds ratio 3.91 (95% confidence interval (CI)
2.40 to 6.36). Many patients experience unpleasant side
* Correspondence: esc5@york.ac.uk
York Trials Unit, Department of Health Sciences, University of York, Seebohm
Rowntree Building (Area 4), York, YO10 5DD, UK
Cockayne and Trials 2010, 11:12
http://www.trialsjournal.com/content/11/1/12
TRIALS
© 2010 Cockayne and The EVERT Trial Team; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
effects such as pain and blistering during cryotherapy
treatment, yet the same review found no evidence to
suggest that it is more effective than treatment with
topical agents such as salicylic acid. Only two trials were
identified which compared salicylic acid and/or lactic
acid with cryotherapy, and they found no difference in
the efficacy between the treatments (odds ratio 1.15,
95% CI 0.72 to 1.82). However, both trials were reported
as low quality, due to unclear allocation concealment,
inadequate blinding procedures, small sample sizes and
inappropriate follow-up and analysis. There is a need,
therefore, for a high quality randomised controlled trial
with a cost-effectiveness analysis to ascertain which is
the better approach for the treatment of verrucae.
The primary objective of the EVERT trial is to com-
pare the clinical effectiveness of cryotherapy versus sal-
icylic acid for the treatment of verrucae. Secondary
objectives are to compare the cost-effectiveness of
cryotherapy versus salicylic acid, and to investigate time
to clearance of verrucae, recurrence/clearance of verru-
cae at six months, patient satisfaction with treatment,
pain associated with treatment, and use of painkillers
for the two treatments.
Methods
Design
This is an open, pragmatic, two-arm, multicentre, ran-
domised controlled trial. Patients with verrucae are ran-
domised equally to cryotherapy using liquid nitrogen
delivered by a healthcare professional (a podiatrist, prac-
tice nurse or GP) or once daily self-treatment with 50%
salicylic acid paste (Verrugon; William Ransom & Son
Plc, Hitchin, UK). Two hundred and sixty-six patients
are being enrolled into the study at recruiting sites in
the UK and Southern Ireland for a period of 24 weeks,
with treatment lasting a maximum of 8 or 9 weeks. The
primary outcome is assessed at 12 weeks. Recruitment
started in October 2006 and will continue until approxi-
mately December 2009. The study has been approved by
the Trent Multi-centre Research Ethics Committee
(Reference Number 04/mre04/59), the Medicines and
Healthcare Products Regulatory Agency (MHRA), The
Irish Medicines Board (IMB) and the ethics or National
Health Service (NHS) research and development com-
mittee responsible for each site. The study is being con-
ducted in accordance with the ethical principles in the
Declaration of Helsinki and good practice guidelines on
the proper conduct of research.
Participants
Patients are eligible if they (i) have a verruca that in the
opinion of the healthcare professional is suitable for
treatment with both salicylic acid and cryotherapy and
(ii) are aged 12 years and over. Patients are excluded if
they (i) are currently in a trial evaluating other
treatments for their verruca, (ii) have impaired healing
e.g. due to diabetes, peripheral vascular disease or any
other condition which means the patient has impaired
healing, (iii) are immunosuppressed e.g. have agamma-
globulinaemia, or are currently taking immunosuppres-
sant drugs such as oral corticosteroids, (iv) are unable
to give informed consent, (v) are currently on renal dia-
lysis, (vi) have cold intolerance e.g. Raynaud’s syndrome
or cold urticaria, or (vii) have any of the following con-
ditions: blood dyscrasias of unknown origin, cryoglobuli-
naemia, cryofibrinogenaemia, collagen and auto-immune
disease.
Recruitment is taking place in both podiatry outpati-
ent clinics (hospital-based or university podiatry school-
based) and general practice at eight recruiting sites in
the UK and one in Southern Ireland. To aid recruit-
ment, a number of strategies have been adopted to
increase the number of patients presenting to the clinics
and GP practices e.g. the trial has been advertised at
pharmacies, GP surgery waiting rooms, swimming pools,
libraries and secondary schools local to the recruiting
sites.
All patients, and their parent/guardian for patients
under the age of 16 years, are given written information
about the study and opportunity to discuss the study
with the trial coordinator and/or site investigator prior
to their decision whether to take part. Written informed
consent is obtained from the patient, or the parent/
guardian for those under 16 years, prior to being rando-
mised. The healthcare professional at the recruiting site
randomises the patient using the remote, independent
York Trials Unit (University of York, UK) telephone or
web-based randomisation service. Randomisation is sim-
ple, that is it is not restricted in any way, for example
by stratification or blocked allocation. The allocation
sequence is computer generated, with the treatment
allocation being concealed from both the healthcare
professional and York Trials Unit until the moment of
randomisation.
Interventions
For patients randomised to cryotherapy using liquid
nitrogen, treatment is delivered by the healthcare profes-
sional according to the usual practice of each trial site.
Prior to treatment, the callus surrounding the verruca(e)
may be debrided (e.g. with a scalpel or file) with any
haemorrhages stopped by digital pressure only. The tis-
sue surrounding the verruca may be masked (e.g. with
petroleum jelly) or left unmasked. Liquid nitrogen is
then applied using a spray (method of choice if avail-
able), probe or cotton bud, until the healthcare profes-
sional is satisfied that the tissue has been frozen
adequately. Silver nitrate may not be applied to the site.
If necessary, after treatment the healthcare professional
may pad the area surrounding the verruca e.g. with 7
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mm felt cavitied padding. The patient is recommended
to use painkillers as they would for a headache if the
area is very painful. All patients are given a follow-up
appointment at 2 weeks as a safety check and for further
cryotherapy if considered necessary. Patients return up
to two more times for further cryotherapy if required
(up to a maximum of four treatments), with 14 to 21
days between treatments. All participants are given a
follow-up appointment at 12 weeks for the primary out-
come assessment.
Patients randomised to self-treatment with 50% sal-
icylic acid are instructed by the healthcare professional
how to use the salicylic acid paste at the first trial
appointment. Thereafter, the acid paste is applied daily
by the patient (or parent/guardian if appropriate) for a
maximum of 8 weeks as per the manufacturer’s instruc-
tions. All patients are given a follow-up appointment at




The primary outcome is complete clearance of all ver-
rucae at 12 weeks as observed on digital photographs
taken by the healthcare professional delivering the
treatment at baseline and 12 weeks and assessed by an
independent healthcare professional. Blinded health-
care professional assessment of clearance is also per-
formed at the 12 week appointment, to be used if for
some reason the digital photograph is not interpreta-
ble. Clearance of verrucae is defined as the restoration
of normal skin upon close inspection, as assessed by
the healthcare professional. Participants who do not
attend their 12 week outcome assessment appointment
are asked if they are willing to take a digital photo-
graph of their foot.
Secondary outcomes
Secondary outcomes are time to clearance of verrucae,
clearance of verrucae at six months, pain intensity of
the first treatment (on a scale of 0 to 10, where 0 is no
pain and 10 is the worst pain imaginable), use of pain-
killers due to verruca treatment (number of days pain-
killers taken), and patient satisfaction with the treatment
(on a 5 point scale, from ‘very unhappy’ to ‘very happy’).
All secondary outcome measures are self-reported by
the patient and assessed by questionnaire (either paper
or web-based according to the patient’s preference),
which patients are requested to complete at baseline,
just after the first treatment and at 1, 3, 12 and 24
weeks. Patients are supplied with a form to return to
York Trials Unit when their verruca has gone.
For the economic evaluation, data on the number of
visits to healthcare professionals in relation to verruca
treatment (trial investigator and any other) and cost of
other verruca treatments purchased by the patient are
collected in the 12 week questionnaire completed by the
patient and from clinic records of attendance.
Further data collected
Other data collected in the questionnaires completed by
the patients include pain associated with the verrucae
(on a 5 point scale, from ‘not at all’ to ‘extremely’),
number of days over a two week period the patient has
self-treated with salicylic acid, reasons for seeking treat-
ment for the verruca(e), how long the patient has had
the verruca(e), whether they received previous treatment
for the verruca(e), willingness to receive the same treat-
ment again if they had another verruca, if the patient
had to stop treatment, reasons for this and whether they
started another treatment, number of previous verrucae
and age at which they occurred. Treatment details for
both groups, number and type of verrucae and partici-
pant’s treatment preference are collected via a question-
naire completed by the healthcare professional. Data on
adverse events, self-reported by the patient (verbally
and/or by questionnaire) or elicited by the healthcare
professional following questioning of the patient at each
study visit, are collected.
Sample size
The Cochrane systematic review [3] found only one
small trial directly comparing the effectiveness of a che-
mical treatment, salicylic acid, with cryotherapy in
patients with warts on their feet alone [4]. This poor
quality study found a 58% cure rate among the patients
allocated to cryotherapy compared with 41% among
those treated with salicylic acid. This difference of 17%
was not statistically significant. The overall cure rates
from this study are smaller than those observed in two
placebo controlled trials of salicylic acid, both of which
reported cure rates of 85% for active treatment, possibly
because more resistant verrucae were included in the
study comparing cryotherapy with salicylic acid. The
EVERT trial is powered to show a 15% difference in
effectiveness. Sufficient patients will be recruited to give
80% power (5% two sided significance) to show a differ-
ence in cure rates of 70% versus 85% at 12 weeks. This
requires 120 patients in each group; after allowing for a
10% drop-out rate, 133 will be required in each treat-
ment group (i.e. 266 in total).
Statistical analysis
Data on baseline demographics such as gender, age, type
and duration of verrucae, and previous treatments will
be summarised and descriptive summary statistics pro-
vided. For variables with continuous measures we will
report the mean and standard deviation. For categorical
data we will report numbers and percent.
Analysis will be by ‘intention to treat’. All patients will
be included in their initially randomised groups whether
or not they received their allocated treatment. Analyses
will be conducted blind to group. There will be a single
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primary analysis at the end of the study using 5% two
sided significance tests. The primary outcome is com-
plete clearance of all verrucae at 12 weeks. The two
treatment groups will be compared using simple propor-
tions of cure or not cured using the Chi squared test.
For the secondary outcomes stricter statistical levels of
significance will be adopted (i.e. p = 0.01) to reduce the
chance of type I error. Survival analysis of patient self-
reported time to clearance of verrucae, censoring for
loss to follow up, will be tested for using Cox regression
adjusting for relevant co-variates to be defined before
the analysis. The recurrence/clearance of verrucae at 6
months will be analysed in the same way as the primary
outcome measure. The primary analysis will be repeated,
but controlling for age, whether or not the verruca has
been previously treated and type of verruca. Should
numbers be sufficient, in order to examine whether
mosaic verrucae respond less well to treatment than
simple verrucae, the primary analysis will be repeated,
but the type of verruca mosaic/simple will be included
as a covariate and also an interaction term verruca
type*treatment will be included [5]. As patients and
healthcare professionals are not blinded to treatment,
we will carry out a second, sub group analysis, assessing
the influence of participant’s treatment preference on
treatment outcomes and the results of the cost-effective-
ness analysis.
Data on side effects and pain intensity during and
after treatment, use of painkillers, reasons for seeking
treatment for the verruca, treatment details, patient
satisfaction with treatment and number of verrucae, will
be summarised and descriptive summary statistics pro-
vided. The number of patients discontinuing treatment
prematurely for any reason will be summarised by treat-
ment group and by reasons for discontinuation. The
incidence of all suspected adverse treatment reactions
will be summarised by treatment group.
For each outcome measure, the number of non-
responders (missing data) will be calculated for each
treatment group. We shall compare at each follow-up
point the number and proportion of non-responders in
each group and the type of non-responder e.g. propor-
tion of males not responding in each group. Appropriate
methods for dealing with missing data will be employed
and sensitivity analyses performed.
Economic analysis
The primary economic evaluation will be a cost-effec-
tiveness analysis of the trial treatments. The evaluation
will be carried out from the perspective of health ser-
vices, which includes both NHS and non-NHS health
related costs, over a time horizon of 12 weeks. The cost
of resource use will be calculated for each trial partici-
pant using the data collected on the number of visits to
healthcare professionals in relation to verruca treatment
and cost of other verruca treatments purchased by the
patient. Staff costs will be calculated using standard
NHS costs [6]. Topical treatments will be costed using
the British National Formulary [7] and manufacturer’s
costs where required. Patient outcome will be measured
as the primary outcome i.e. complete clearance of all
verrucae at 12 weeks. The incremental mean difference
in costs between the two trial arms and incremental dif-
ference in patient outcome will be calculated and we
will calculate an incremental cost effectiveness ratio of
cost per patient cured at 12 weeks. If cryotherapy is less
costly than salicylic acid and more effective or if
cryotherapy is more costly but less effective, then one
treatment clearly dominates the other and there is a
clear choice about the treatment that is cost-effective. If
non-dominance occurs we must weigh up the potential
cost implications versus patient benefit to make a deci-
sion regarding cost-effectiveness. We will do this by
relating the incremental mean costs between the two
trial arms to the incremental mean outcome as a ratio,
the incremental cost-effectiveness ratio (ICER). The
ICER represents the additional cost per additional
patient cured. Uncertainty regarding the cost-effective-
ness analysis will be assessed using cost-effectiveness
acceptability curves.
Study organisation
The University of York is the Sponsor for the trial. The
York Trials Unit at the University of York is coordinat-
ing the study, monitoring and verifying the data and will
analyse the results. A Trial Steering Committee (TSC),
consisting of an independent chair and two other inde-
pendent members along with the lead investigator and
other study collaborators, oversees the conduct of the
trial. An independent Data Monitoring and Ethics Com-
mittee (DMEC), comprising of an independent statisti-
cian, podiatrist and Research Fellow has been set up to
review safety and outcome data. Further details about
the trial are available at the EVERT Trial Website [8].
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